Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Progression precursors in CLL

Othman Al-Sawaf • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Lymphoma

Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, discusses two different progression precursors in chronic lymphocytic leukemia (CLL), and their indicative ability in a clinical setting. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Othman Al-Sawaf

1:47
Treatment of Richter’s transformation: recent insights
Othman Al-Sawaf • 16 Jun 2023
1:26
The expanding landscape of next-generation BTK inhibitors in CLL
Othman Al-Sawaf • 16 Jun 2023
0:56
Fixed-duration treatment strategies for frontline and relapsed CLL
Othman Al-Sawaf • 16 Jun 2023
1:43
Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL
Othman Al-Sawaf • 16 Jun 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals